Loading...
Header Logo
Keywords
Last Name
Institution

JANOS ROSZIK

TitleAssistant Professor
InstitutionMD Anderson
DepartmentMelanoma Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Roszik J, Subbiah V. Mining Public Databases for Precision Oncology. Trends Cancer. 2018 07; 4(7):463-465. PMID: 29937043.
      View in: PubMed
    2. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168. PMID: 27776519.
      View in: PubMed
    3. Roszik J, Tóth G, Szöllosi J, Vereb G. Validating pharmacological disruption of protein-protein interactions by acceptor photobleaching FRET imaging. Methods Mol Biol. 2013; 986:165-78. PMID: 23436412.
      View in: PubMed
    4. Beyer D, Tándor I, Kónya Z, Bátori R, Roszik J, Vereb G, Erdodi F, Vasas G, M-Hamvas M, Jambrovics K, Máthé C. Microcystin-LR, a protein phosphatase inhibitor, induces alterations in mitotic chromatin and microtubule organization leading to the formation of micronuclei in Vicia faba. Ann Bot. 2012 Sep; 110(4):797-808. PMID: 22819947.
      View in: PubMed
    5. Roszik J, Rabinovich B, Cooper LJ. Imaging of T cells expressing chimeric antigen receptors. Immunotherapy. 2011 Dec; 3(12):1411-4. PMID: 22091674.
      View in: PubMed
    6. Váradi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, Galmarini CM, Szöllosi J, Nagy P. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur J Pharmacol. 2011 Sep 30; 667(1-3):91-9. PMID: 21658382.
      View in: PubMed
    7. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports. 6.
    8. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Molecular Cancer Therapeutics. 15:2442-2454.
    9. Clinicopathological features and clinical outcomes associated with TP53 and BRAFN on- V 600 mutations in cutaneous melanoma patients. Cancer.
    10. Homogeneous finite-source retrial queues with server subject to breakdowns and repairs. Mathematical and Computer Modelling. 42:673-682.
    11. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell and Melanoma Research. 28:357-359.
    12. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell and Melanoma Research.
    13. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 28:515-528.
    14. Retrial queues in the performance modeling of cellular mobile networks using mosel. International Journal of Simulation: Systems, Science and Technology. 6:38-47.
    15. Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clinical Cancer Research. 22:3016-3024.
    16. Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. Molecular Imaging and Biology. 1-11.
    17. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 167:397-404.e9.
    18. Heterogeneous finite-source retrial queues with server subject to breakdowns and repairs. Journal of Mathematical Sciences. 132:677-685.
    19. The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget. 8:3-14.
    20. Cancer Discovery. 6:202-216.
    21. Modeling finite-source retrial queueing systems with unreliable heterogeneous servers and different service policies using mosel. 75-80.
    22. Cytoskeletal and developmental alterations in Ceratophyllum demersum induced by microcystin-LR, a cyanobacterial toxin. Aquatic Botany. 92:179-184.
    23. RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. Oncotarget. 7:36711-36718.
    24. Performance analysis of finite-source retrial queues operating in random environments. International Journal of Operational Research. 2:254-268.
    25. Traffic load in a wireless multihop network. 9-17.
    26. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia.
    27. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports. 6.
    28. Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clinical Cancer Research. 22:374-382.
    29. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proceedings of the National Academy of Sciences of the United States of America. 113:5999-6004.
    30. Performance analysis of finite-source retrial queues with nonreliable heterogenous servers. Journal of Mathematical Sciences. 146:6033-6038.
    31. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine. 14.
    ROSZIK's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description